Health Canada approves Moderna’s mRNA flu and flu-COVID combo vaccines
Health Canada approved Moderna's mRNA flu vaccine (mFLUSIVA) and a combo flu-COVID vaccine (mCOFLU) for adults 50+. Moderna stated the vaccines won't be available this season. The National Advisory Committee on Immunization recommends non-mRNA flu shots for all ages 6+ and COVID-19 vaccines for those 65+ and long-term care residents. Moderna's vaccines were previously approved in the U.S. and Europe.
How this was made
The 30-second read
Why it matters
The approval expands Moderna's product portfolio and may drive revenue growth, though distribution timing could affect near‑term earnings.
Market read
Regulatory clearance is a primary catalyst for Moderna, likely prompting a positive stock reaction, while supply concerns may limit the immediate impact.
What to watch
Potential competition from existing flu vaccines and pricing negotiations with Canadian health authorities.
Background
Moderna's mRNA flu vaccine (mFLUSIVA) and flu‑COVID combo (mCOFLU) received Health Canada approval for adults 50+, but the company warned they may not reach pharmacies before the flu season.
Ticker impact
Health Canada approved Moderna's mRNA flu vaccine and its flu‑COVID combo, a first for the company in Canada.
likely upward pressure as the market prices in the regulatory win
Regulatory clearance is a material catalyst for a large biotech; no competing approval was previously reported.
Market effects
May boost the broader vaccine and mRNA biotech sector as a new indication gains approval.
Positive for Canadian biotech stocks and could influence health‑care indices in Canada.
Adds to global mRNA pipeline momentum, supporting sentiment for similar companies worldwide.
Counterpoint
Supply constraints could delay revenue, limiting short‑term upside.
Key entities
- CompanyModerna Inc.
Developer of the approved mRNA flu and flu‑COVID vaccines.
- RegulatorHealth Canada
Canadian health authority that granted the approvals.
